Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Open Innovation for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Due Diligence
Comparison
 
Due Diligence
Overview
Top Applications
Online Panel Discussions
Request Consultation
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 31 - per page Next page
Order by
25 and 50 mg diclofenac K film coated immediate release tablets More
Using a lamellar structure as a delivery system, the Sulidin® Nimesulide LPS gel provides enhanced percutaneous penetration of Nimesulide and reduced yellow staining on the skin. LPS Technology worldwide patents are pending. More
5 and 10 mg Donepezil as well as 4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
The First Line of Therapy in Severe Migraine Attacks More
Diclofenac transdermal delivery system for the treatment of inflammatory and painful conditions More
25mg dosage strenght for the OTC market in film coated tablets More
Collagen-based biodegradable matrices for localized drug delivery More
Adhesive Patch of 90 sq. cm. and containing as active ingredient 100 mg. of ketoprofen for the local treatment of traumatic injuries and extra-articular rheumatism More
4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
25mg dosage strenght for the OTC market More
Displaying 1..10 of 31 - per page Next page
Order by

Your selection

Industry sector
Pharmaceutical del
Therapeutic target
Central Nervous System del
Development phase
Phase III del

Browse By

Research Partnership for Due Diligence Execution
EuroPLX 39 + 40
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us